Concr in use

Use case

NCT06409221: Clinical trial assessing FarrSight®-Twin in triple-negative breast cancer

Use case

NCT04750109: Patient-level FarrSight®-Twin predictions using tissue and liquid diagnostics in cancer of unknown primary

Use case

Helping pharma with indication expansion for a best-in-class inhibitor

Use case

Simulating APACT pancreatic cancer trial in silico using RWD

Use case

Helping a biotech with drug combinations and indication expansion for a first-on-class inhibitor

Read our latest results

News and insights

Partnerships

Our partners leverage Concr advanced predictive modelling across every stage of therapeutic development to create shared value for the benefit of cancer patients.

Partnerships

FarrSight®

Our cloud-based platform effectively integrates diverse data parcels to generate meaningful insights.

Platform